{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T03:27:07Z","timestamp":1772335627045,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003593","name":"CNPq","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004901","name":"FAPEMIG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"CAPES","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.thromres.2025.109427","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T23:16:20Z","timestamp":1754954180000},"page":"109427","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The role of interleukin-10 gene variants in inhibitor development in hemophilia: A meta-analysis"],"prefix":"10.1016","volume":"253","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5596-0330","authenticated-orcid":false,"given":"Alessandra Faustino","family":"da Concei\u00e7\u00e3o Bezerra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5463-3012","authenticated-orcid":false,"given":"Yanka Karolinna","family":"Batista-Rodrigues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3083-7093","authenticated-orcid":false,"given":"Suely Meireles","family":"Rezende","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9479-4432","authenticated-orcid":false,"given":"Renan Pedra de","family":"Souza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2025.109427_bb0005","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1056\/NEJM199401063300108","article-title":"Hemophilia A","volume":"330","author":"Hoyer","year":"1994","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 6","key":"10.1016\/j.thromres.2025.109427_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"Wfh guidelines for the management of Hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2025.109427_bb0015","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1046\/j.1365-2516.2000.00045.x","article-title":"Inhibitors in haemophilia: a primer","volume":"6","author":"DiMichele","year":"2000","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2025.109427_bb0020","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3324\/haematol.2019.239160","article-title":"Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study","volume":"106","author":"Male","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.thromres.2025.109427_bb0025","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1182\/blood-2012-09-457036","article-title":"Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia a: the RODIN study","volume":"121","author":"Gouw","year":"2013","journal-title":"Blood"},{"issue":"Suppl. 77","key":"10.1016\/j.thromres.2025.109427_bb0030","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/ejh.12495","article-title":"Genetic risk factors for inhibitors in haemophilia A","volume":"94","author":"Bardi","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.thromres.2025.109427_bb0035","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1615\/CritRevImmunol.v32.i1.30","article-title":"Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease","volume":"32","author":"Iyer","year":"2012","journal-title":"Crit. Rev. Immunol."},{"key":"10.1016\/j.thromres.2025.109427_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12878-014-0019-8","article-title":"The IL-10 polarized cytokine pattern in innate and adaptive immunity cells contribute to the development of FVIII inhibitors","volume":"15","author":"Silveira","year":"2015","journal-title":"BMC Hematol."},{"key":"10.1016\/j.thromres.2025.109427_bb0045","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.cytogfr.2017.11.003","article-title":"Cytokines in the pathogenesis of hemophilic arthropathy","volume":"39","author":"Wojdasiewicz","year":"2018","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.thromres.2025.109427_bb0050","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.thromres.2025.109427_bb0055","doi-asserted-by":"crossref","first-page":"e010403","DOI":"10.1136\/bmjopen-2015-010403","article-title":"Empirical evaluation of the Q-Genie tool: a protocol for assessment of effectiveness","volume":"6","author":"Sohani","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.thromres.2025.109427_bb0060","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1182\/blood-2005-09-3918","article-title":"Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A","volume":"107","author":"Astermark","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2025.109427_bb0065","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1111\/j.1538-7836.2009.03636.x","article-title":"Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A","volume":"7","author":"Pavlova","year":"2009","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2025.109427_bb0070","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1365-2516.2009.02150.x","article-title":"Polymorphisms in genes involved in autoimmune disease and the risk of FVIII inhibitor development in Italian patients with haemophilia A","volume":"16","author":"Bafunno","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2025.109427_bb0075","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1744-313X.2009.00893.x","article-title":"Analysis of cytokine genes polymorphism as markers for inhibitor development in haemophilia A","volume":"37","author":"Chaves","year":"2010","journal-title":"Int. J. Immunogenet."},{"key":"10.1016\/j.thromres.2025.109427_bb0080","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1365-2516.2010.02473.x","article-title":"A case-control study reveals immunoregulatory gene haplotypes that influence inhibitor risk in severe haemophilia A","volume":"17","author":"Lozier","year":"2011","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2025.109427_bb0085","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1160\/TH11-06-0425","article-title":"Impact of polymorphisms in genes involved in autoimmune disease on inhibitor development in Chinese patients with haemophilia A","volume":"107","author":"Lu","year":"2012","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2025.109427_bb0090","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1055\/s-0037-1619751","volume":"31","author":"Wieland","year":"2011","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.thromres.2025.109427_bb0095","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/j.1365-2516.2012.02845.x","article-title":"Immune regulatory gene polymorphisms as predisposing risk factors for the development of factor VIII inhibitors in Indian severe haemophilia A patients","volume":"18","author":"Pinto","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2025.109427_bb0100","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/j.1365-2516.2012.02882.x","article-title":"Polymorphic miRNA-mediated gene contribution to inhibitor development in haemophilia A","volume":"18","author":"Bafunno","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2025.109427_bb0105","doi-asserted-by":"crossref","first-page":"e416","DOI":"10.1111\/hae.12015","article-title":"Immune system polymorphisms and factor VIII inhibitor formation in Brazilian haemophilia A severe patients","volume":"18","author":"Agostini","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2025.109427_bb0110","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/hae.12168","article-title":"Impact of HLA alleles and cytokine polymorphisms on inhibitors development in children with severe haemophilia A","volume":"19","author":"Pergantou","year":"2013","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2025.109427_bb0115","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4274\/Tjh.2012.0197","article-title":"A polymorphism in the IL-5 gene is associated with inhibitor development in severe hemophilia A patients","volume":"31","author":"Fidanc\u0131","year":"2014","journal-title":"Turk. J. Haematol."},{"key":"10.1016\/j.thromres.2025.109427_bb0120","doi-asserted-by":"crossref","first-page":"e286","DOI":"10.1111\/hae.12684","article-title":"Risk factors associated with inhibitor development in Chinese patients with haemophilia B","volume":"21","author":"Zhou","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2025.109427_bb0125","doi-asserted-by":"crossref","first-page":"e312","DOI":"10.1111\/hae.12685","article-title":"New associations: INFG and TGFB1 genes and the inhibitor development in severe haemophilia A","volume":"21","author":"de Alencar","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2025.109427_bb0130","doi-asserted-by":"crossref","first-page":"e518","DOI":"10.1111\/hae.13344","article-title":"Association of factor VIII and factor IX mutations, HLA Class II, tumour necrosis factor-\u03b1 and interleukin-10 on inhibitor development among Thai haemophilia A and B patients","volume":"23","author":"Chuansumrit","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2025.109427_bb0135","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1080\/15513815.2017.1281363","article-title":"The development of FVIII inhibitors in relation to IL10 gene polymorphism in hemophilia a Egyptian pediatric patients","volume":"36","author":"Sadek","year":"2017","journal-title":"Fetal Pediatr. Pathol."},{"key":"10.1016\/j.thromres.2025.109427_bb0140","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2174\/1871529X19666190206152315","article-title":"Relationship between single-nucleotide polymorphisms of tumor necrosis factor alpha, interleukin-10, factor II and factor V with risk of inhibitor development in patients with severe hemophilia A","volume":"19","author":"Soori","year":"2019","journal-title":"Cardiovasc. Hematol. Disord. Drug Targets"},{"key":"10.1016\/j.thromres.2025.109427_bb0145","doi-asserted-by":"crossref","first-page":"e0218258","DOI":"10.1371\/journal.pone.0218258","article-title":"Risk stratification integrating genetic data for factor VIII inhibitor development in patients with severe hemophilia A","volume":"14","author":"Bachelet","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.thromres.2025.109427_bb0150","doi-asserted-by":"crossref","first-page":"e166","DOI":"10.1111\/hae.13194","article-title":"A prevalent CTLA4 missense variant significantly associates with inhibitor development in Argentine patients with severe haemophilia A","volume":"23","author":"Marchione","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2025.109427_bb0155","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.cytogfr.2010.09.002","article-title":"Biology of interleukin-10","volume":"21","author":"Sabat","year":"2010","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.thromres.2025.109427_bb0160","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1089\/jir.2006.0184","article-title":"Assessment of in vitro cytokine response in hemophilia A patients with or without factor VIII inhibitory antibody","volume":"27","author":"Towfighi","year":"2007","journal-title":"J. Interf. Cytokine Res."},{"key":"10.1016\/j.thromres.2025.109427_bb0165","doi-asserted-by":"crossref","first-page":"102436","DOI":"10.1016\/j.rpth.2024.102436","article-title":"High levels of anti-factor VIII immunoglobulin G4 and immunoglobulin G total are associated with immune tolerance induction failure in people with congenital hemophilia a and high-responding inhibitors","volume":"8","author":"Chaves","year":"2024","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2025.109427_bb0170","first-page":"1197","article-title":"Clinical significance of the levels of peripheral blood Tregs and cytokines IL-35, TGF-\u03b2 and IL-10 in hemophilia a patients with FVII inhibitor","volume":"32","author":"He","year":"2024","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.thromres.2025.109427_bb0175","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10753-012-9517-7","article-title":"Is the IL-10 promoter polymorphism at position-592 associated with immune system-related diseases?","volume":"36","author":"Karimabad","year":"2013","journal-title":"Inflammation"},{"key":"10.1016\/j.thromres.2025.109427_bb0180","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S0198-8859(02)00440-8","article-title":"Frequency of cytokine polymorphisms in populations from western Europe, Africa, Asia, the Middle East and South America","volume":"63","author":"Meenagh","year":"2002","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.thromres.2025.109427_bb0185","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cell.2019.02.048","article-title":"The missing diversity in human genetic studies","volume":"177","author":"Sirugo","year":"2019","journal-title":"Cell"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004938482500177X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004938482500177X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T15:28:17Z","timestamp":1761406097000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004938482500177X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":37,"alternative-id":["S004938482500177X"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2025.109427","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of interleukin-10 gene variants in inhibitor development in hemophilia: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2025.109427","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109427"}}